Kestra Medical Technologies (NASDAQ: KMTS) insider details 51,900-share stock sale

Rhea-AI Filing Summary

Kestra Medical Technologies, Ltd. reports a planned sale of up to 51,900 common shares through Merrill Lynch on NASDAQ, with an aggregate value of $1,272,585.45. The shares relate to a 07/17/2026 performance stock issuance granted under an equity compensation plan and follow multiple prior common share sales over recent months.

Key Figures

Planned shares to be sold: 51,900 shares Aggregate value of planned sale: $1,272,585.45 CUSIP-like identifier: 58602497 +5 more

8 metrics

Planned shares to be sold 51,900 shares Common stock planned for sale through Merrill Lynch on NASDAQ

Aggregate value of planned sale $1,272,585.45 Total value associated with 51,900 common shares

CUSIP-like identifier 58602497 Identifier listed with the common stock in the securities information

Grant date of performance stock 07/17/2026 Performance Stock Issuance granted under equity compensation plan

Sale 1 15,000 shares; $300,671.04 Common share sale by Brian Webster on 04/15/2026

Sale 2 15,000 shares; $314,329.85 Common share sale by Brian Webster on 05/15/2026

Sale 3 15,000 shares; $312,142.94 Common share sale by Brian Webster on 06/15/2026

Sale 4 13,017 shares; $311,424.12 Common share sale by Brian Webster on 08/03/2026

Key Terms

Performance Stock Issuance, equity compensation plan, Common Shares

3 terms

Performance Stock Issuance financial

"Common Stock | 07/17/2026 | Performance Stock Issuance |"

equity compensation plan financial

"Granted as part of issuer equity compensation plan"

A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.

Common Shares financial

"Common Shares | 04/15/2026 | 15000 | 300671.04"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/04/2026 - 04:36 PM Accepted by SEC EDGAR 08/04/2026 - 04:35 PM Learn about SEC filing dates

FAQ

What does Kestra Medical Technologies (KMTS) disclose in this Form 144?

Kestra Medical Technologies discloses a planned sale of 51,900 common shares with an aggregate value of $1,272,585.45. The notice also lists several prior common share sales by Brian Webster over recent months, including dates, share amounts, and total sale values.

How many KMTS shares are planned for sale and through whom?

The filing lists a planned sale of 51,900 common shares of Kestra Medical Technologies. The securities are to be sold through Merrill Lynch on the NASDAQ, with the total value for this block indicated as $1,272,585.45 in the disclosure.

What is the value of the KMTS shares covered by the planned sale?

The planned sale covers common shares with an aggregate value of $1,272,585.45. This amount corresponds to the 51,900 KMTS shares identified for potential sale through Merrill Lynch on NASDAQ, as reported in the Form 144 securities information section.

How were the KMTS shares obtained that are referenced in this filing?

The KMTS shares referenced were associated with a performance stock issuance on 07/17/2026. They were granted as part of an issuer equity compensation plan by Kestra Medical Technologies, as described in the securities to be sold section of the disclosure.

What prior KMTS share sales by Brian Webster are disclosed?

The filing lists several prior KMTS common share sales by Brian Webster, including 15,000 shares on 04/15/2026 for $300,671.04 and similar 15,000-share sales on later monthly dates, plus additional sales on 07/30/2026, 07/31/2026, and 08/03/2026 with specified values.

On which market are the KMTS shares in this filing traded?

The common shares referenced in the disclosure are traded on the NASDAQ market. The securities information section identifies NASDAQ as the trading venue for the 51,900 Kestra Medical Technologies shares to be sold through Merrill Lynch.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch 225 Liberty St New York NY 10281	51900	1272585.45	58602497	08/04/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/17/2026	Performance Stock Issuance	KESTRA MEDICAL TECHNOLOGIES, LTD.			51900	07/17/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	04/15/2026	15000	300671.04
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	05/15/2026	15000	314329.85
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 Common Shares WA 98033	Common Shares	06/15/2026	15000	312142.94
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	07/15/2026	15000	336609.41
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	07/30/2026	7857	178531.04
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	07/31/2026	8948	202259.77
Brian Webster 3933 LAKE WASHINGTON BLVD NE Suite 200 KIRKLAND WA 98033	Common Shares	08/03/2026	13017	311424.12

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)